Selected research
Industry Research
Epigenetics Industry Research Report 2026
Market perspective
The global Epigenetics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Epigenetics market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Epigenetics market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Epigenetics market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Epigenetics include Abcam, Active Motif, Agilent, Bio-Rad, CellCentric Ltd., Diagenode, EpiGentek, Epizyme Inc. and Illumina, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Epigenetics market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Epigenetics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Epigenetics Market by Company
Abcam
Active Motif
Agilent
Bio-Rad
CellCentric Ltd.
Diagenode
EpiGentek
Epizyme Inc.
Illumina
New England Biolabs
Perkinelmer
Qiagen
ValiRx plc
Zymo Research
Merck & Co.
Thermo Fisher Scientific
Epigenetics Segment by Type
Enzymes
Reagents
Kits & Assays
Instruments and Consumables
Epigenetics Segment by Application
Contract Research Organizations (CROs)
Biotechnology Companies
Academic & Research Institutes
Pharmaceutical Companies
Others
Epigenetics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Epigenetics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Epigenetics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Epigenetics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Epigenetics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Enzymes
- Reagents
- Kits & Assays
- Instruments and Consumables
Applications
- Contract Research Organizations (CROs)
- Biotechnology Companies
- Academic & Research Institutes
- Pharmaceutical Companies
- Others
Companies covered
- Abcam
- Active Motif
- Agilent
- Bio-Rad
- CellCentric Ltd.
- Diagenode
- EpiGentek
- Epizyme Inc.
- Illumina
- New England Biolabs
- Perkinelmer
- Qiagen
- ValiRx plc
- Zymo Research
- Merck & Co.
- Thermo Fisher Scientific
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Epigenetics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Enzymes
- 2.2.3 Reagents
- 2.2.4 Kits & Assays
- 2.2.5 Instruments and Consumables
- 2.3 Epigenetics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Contract Research Organizations (CROs)
- 2.3.3 Biotechnology Companies
- 2.3.4 Academic & Research Institutes
- 2.3.5 Pharmaceutical Companies
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Epigenetics Breakdown Data by Type
- 3.1 Global Epigenetics Historic Market Size by Type (2021-2026)
- 3.2 Global Epigenetics Forecasted Market Size by Type (2027-2032)
4 Epigenetics Breakdown Data by Application
- 4.1 Global Epigenetics Historic Market Size by Application (2021-2026)
- 4.2 Global Epigenetics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Epigenetics Market Perspective (2021-2032)
- 5.2 Global Epigenetics Growth Trends by Region
- 5.2.1 Global Epigenetics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Epigenetics Historic Market Size by Region (2021-2026)
- 5.2.3 Epigenetics Forecasted Market Size by Region (2027-2032)
- 5.3 Epigenetics Market Dynamics
- 5.3.1 Epigenetics Industry Trends
- 5.3.2 Epigenetics Market Drivers
- 5.3.3 Epigenetics Market Challenges
- 5.3.4 Epigenetics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Epigenetics Players by Revenue
- 6.1.1 Global Top Epigenetics Players by Revenue (2021-2026)
- 6.1.2 Global Epigenetics Revenue Market Share by Players (2021-2026)
- 6.2 Global Epigenetics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Epigenetics Head Office and Area Served
- 6.4 Global Epigenetics Players, Product Type & Application
- 6.5 Global Epigenetics Manufacturers Established Date
- 6.6 Global Epigenetics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Epigenetics Market Size (2021-2032)
- 7.2 North America Epigenetics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Epigenetics Market Size by Country (2021-2026)
- 7.4 North America Epigenetics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Epigenetics Market Size (2021-2032)
- 8.2 Europe Epigenetics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Epigenetics Market Size by Country (2021-2026)
- 8.4 Europe Epigenetics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Epigenetics Market Size (2021-2032)
- 9.2 Asia-Pacific Epigenetics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Epigenetics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Epigenetics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Epigenetics Market Size (2021-2032)
- 10.2 South America Epigenetics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Epigenetics Market Size by Country (2021-2026)
- 10.4 South America Epigenetics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Epigenetics Market Size (2021-2032)
- 11.2 Middle East & Africa Epigenetics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Epigenetics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Epigenetics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Abcam
- 12.1.1 Abcam Company Information
- 12.1.2 Abcam Business Overview
- 12.1.3 Abcam Revenue in Epigenetics Business (2021-2026)
- 12.1.4 Abcam Epigenetics Product Portfolio
- 12.1.5 Abcam Recent Developments
- 12.2 Active Motif
- 12.2.1 Active Motif Company Information
- 12.2.2 Active Motif Business Overview
- 12.2.3 Active Motif Revenue in Epigenetics Business (2021-2026)
- 12.2.4 Active Motif Epigenetics Product Portfolio
- 12.2.5 Active Motif Recent Developments
- 12.3 Agilent
- 12.3.1 Agilent Company Information
- 12.3.2 Agilent Business Overview
- 12.3.3 Agilent Revenue in Epigenetics Business (2021-2026)
- 12.3.4 Agilent Epigenetics Product Portfolio
- 12.3.5 Agilent Recent Developments
- 12.4 Bio-Rad
- 12.4.1 Bio-Rad Company Information
- 12.4.2 Bio-Rad Business Overview
- 12.4.3 Bio-Rad Revenue in Epigenetics Business (2021-2026)
- 12.4.4 Bio-Rad Epigenetics Product Portfolio
- 12.4.5 Bio-Rad Recent Developments
- 12.5 CellCentric Ltd.
- 12.5.1 CellCentric Ltd. Company Information
- 12.5.2 CellCentric Ltd. Business Overview
- 12.5.3 CellCentric Ltd. Revenue in Epigenetics Business (2021-2026)
- 12.5.4 CellCentric Ltd. Epigenetics Product Portfolio
- 12.5.5 CellCentric Ltd. Recent Developments
- 12.6 Diagenode
- 12.6.1 Diagenode Company Information
- 12.6.2 Diagenode Business Overview
- 12.6.3 Diagenode Revenue in Epigenetics Business (2021-2026)
- 12.6.4 Diagenode Epigenetics Product Portfolio
- 12.6.5 Diagenode Recent Developments
- 12.7 EpiGentek
- 12.7.1 EpiGentek Company Information
- 12.7.2 EpiGentek Business Overview
- 12.7.3 EpiGentek Revenue in Epigenetics Business (2021-2026)
- 12.7.4 EpiGentek Epigenetics Product Portfolio
- 12.7.5 EpiGentek Recent Developments
- 12.8 Epizyme Inc.
- 12.8.1 Epizyme Inc. Company Information
- 12.8.2 Epizyme Inc. Business Overview
- 12.8.3 Epizyme Inc. Revenue in Epigenetics Business (2021-2026)
- 12.8.4 Epizyme Inc. Epigenetics Product Portfolio
- 12.8.5 Epizyme Inc. Recent Developments
- 12.9 Illumina
- 12.9.1 Illumina Company Information
- 12.9.2 Illumina Business Overview
- 12.9.3 Illumina Revenue in Epigenetics Business (2021-2026)
- 12.9.4 Illumina Epigenetics Product Portfolio
- 12.9.5 Illumina Recent Developments
- 12.10 New England Biolabs
- 12.10.1 New England Biolabs Company Information
- 12.10.2 New England Biolabs Business Overview
- 12.10.3 New England Biolabs Revenue in Epigenetics Business (2021-2026)
- 12.10.4 New England Biolabs Epigenetics Product Portfolio
- 12.10.5 New England Biolabs Recent Developments
- 12.11 Perkinelmer
- 12.11.1 Perkinelmer Company Information
- 12.11.2 Perkinelmer Business Overview
- 12.11.3 Perkinelmer Revenue in Epigenetics Business (2021-2026)
- 12.11.4 Perkinelmer Epigenetics Product Portfolio
- 12.11.5 Perkinelmer Recent Developments
- 12.12 Qiagen
- 12.12.1 Qiagen Company Information
- 12.12.2 Qiagen Business Overview
- 12.12.3 Qiagen Revenue in Epigenetics Business (2021-2026)
- 12.12.4 Qiagen Epigenetics Product Portfolio
- 12.12.5 Qiagen Recent Developments
- 12.13 ValiRx plc
- 12.13.1 ValiRx plc Company Information
- 12.13.2 ValiRx plc Business Overview
- 12.13.3 ValiRx plc Revenue in Epigenetics Business (2021-2026)
- 12.13.4 ValiRx plc Epigenetics Product Portfolio
- 12.13.5 ValiRx plc Recent Developments
- 12.14 Zymo Research
- 12.14.1 Zymo Research Company Information
- 12.14.2 Zymo Research Business Overview
- 12.14.3 Zymo Research Revenue in Epigenetics Business (2021-2026)
- 12.14.4 Zymo Research Epigenetics Product Portfolio
- 12.14.5 Zymo Research Recent Developments
- 12.15 Merck & Co.
- 12.15.1 Merck & Co. Company Information
- 12.15.2 Merck & Co. Business Overview
- 12.15.3 Merck & Co. Revenue in Epigenetics Business (2021-2026)
- 12.15.4 Merck & Co. Epigenetics Product Portfolio
- 12.15.5 Merck & Co. Recent Developments
- 12.16 Thermo Fisher Scientific
- 12.16.1 Thermo Fisher Scientific Company Information
- 12.16.2 Thermo Fisher Scientific Business Overview
- 12.16.3 Thermo Fisher Scientific Revenue in Epigenetics Business (2021-2026)
- 12.16.4 Thermo Fisher Scientific Epigenetics Product Portfolio
- 12.16.5 Thermo Fisher Scientific Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst